Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting Journal Article
| Authors: | Patel, A.; Ravaud, A.; Motzer, R. J.; Pantuck, A. J.; Staehler, M.; Escudier, B.; Martini, J. F.; Lechuga, M.; Lin, X.; George, D. J. |
| Article Title: | Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting |
| Abstract: | Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median: 6.4 vs 5.9 years; hazard ratio: 0.9; 95% CI: 0.7-1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio: 0.8; 95% CI: 0.6-1.0). Conclusion: Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration: NCT00375674 (ClinicalTrials.gov. © 2020 Pfizer Inc. |
| Keywords: | sunitinib; renal cell carcinoma; platelet; lymphocyte; adjuvant; prognostic |
| Journal Title: | Future Oncology |
| Volume: | 17 |
| Issue: | 4 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2021-02-01 |
| Start Page: | 403 |
| End Page: | 409 |
| Language: | English |
| DOI: | 10.2217/fon-2020-0652 |
| PUBMED: | 33028084 |
| PROVIDER: | scopus |
| PMCID: | PMC8488532 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 March 2021 -- Source: Scopus |
